Suven Life Sciences share news, announcements and annual reports
NSE: SUVENBSE: 530239Healthcare ServicesSmall Cap
Suven Life Sciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Oct 2003 on NSE
Last close ₹258.85down ₹5.35 (2.03%)BSE ₹258.10
Share price at the NSE close on 30 Oct 2026. Previous close ₹264.20.
30 Oct: open ₹263.50, high ₹265.65, low ₹257.00
52-week range of traded prices to 30 Oct 2026
₹124.11Low, 24 Mar 2026₹403.35High, 1 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,314 Cr806th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −100.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −63.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,27,67850.0% delivered
Suven Life Sciences share news and announcements
803 announcements, routine notices left out, newest first. Page 14 of 17.
May 2011
30 May · Disclosure
Compensation Committee in its meeting held on May 30, 2011 had granted 5,00,000 stock options to the eligible employees of the Company under Suven Employees Stock Options Plan(SESOP) - 2004.30 May · Results
19 May · Board meeting
To consider, inter alia, and take on record the following matters : (1) To consider and approve the Audited Annual Accounts for the year ended March 31, 2011; (2) To consider and recommend dividend if any, for the financial year 2010-2011.
Apr 2011
26 Apr · Results
Audited Results of the Company for the last quarter of the year ending March 31, 2011 and for the year ended as on that day will be published before May 30, 2011. In view of this, the Company does not propose to publish un-audited results for the last quarter ending March 31, 2011.
Jan 2011
31 Jan · Updates
21 Jan · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the Third Quarter ended December 31, 2010.
Dec 2010
Nov 2010
12 Nov · Business
Compensation Committee of Board of Directors of the Company allotted 1,95,740 equity shares through circular resolution on November 12, 2010 to the employees under stock option plans of the company. Further, consequent to the above allotment, the paid up share capital of the company has gone up from 116536248 equity shares of Re 1/- each aggregating to Rs. 11,65,36,248 to 116731988 equity shares of Re 1/- each aggregating to Rs 11,67,31,988.
Oct 2010
19 Oct · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the Second Quarter ended September 30, 2010.
Sep 2010
Jul 2010
19 Jul · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the First Quarter ended June 30, 2010.13 Jul · Disclosure
Compensation Committee met on July 12, 2010 and granted 200,000 options to the eligible employees under the Employees Stock Options Plan - 2004 of the Company.
Jun 2010
May 2010
5 May · Business
Compensation Committee of Board of Directors of the Company allotted 6,61,848 equity shares through circular resolution on May 05, 2010 under stock option plans of the company. Further, consequent to the above allotment, the paid up share capital of the company has gone up from 115874400 equity shares of Re 1/- each, aggregating to Rs. 11,58,74,400 to 116536248 equity shares of Re 1/- each aggregating to Rs 11,65,36,248.
Apr 2010
30 Apr · Dividend
Board of Directors in its meeting held on April 30, 2010, has recommended Dividend of Re 0.25 paise per equity share of face value of Re 1/- each (25%) for the financial year ended March 31, 2010, subject to the approval of Members in ensuing Annual General Meeting.30 Apr · News Release
News release dated April 30, 2010, titled "Suven spends 26% of Revenue on R&D for the year ended March 2010". A copy of the release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Apr · Meeting
Company has fixed Book Closure dates for the Register of members and Share Transfer from July 21, 2010 to July 23, 2010 for the purpose of AGM & Dividend Declaration. The Annual General Meeting of the Company will be held on July 27, 2010. Further the Company has informed the Exchange regarding the details as per requirement of clause 20 of the Listing Agreement. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Apr · Dividend
Board of Directors of the Company at its meeting held on April 30, 2010 has recommended Dividend Rs.0.25 paise per equity share of face value of Re 1/- each (25%) for the financial year ended March 31, 2010, subject to the approval of members in ensuing Annual General Meeting.28 Apr · Business
Press release dated April 28, 2010, titled "Suven Life Sciences secures Product Patents from India and New Zealand ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Apr · Board meeting
To Consider, inter alia, and take on record the followings matters: (1) To consider and approve the Audited Annual Accounts for the year ended March 31, 2010. (2) to consider and recommend dividend if any, for the financial year 2009-2010.22 Apr · Business
Press release dated April 22, 2010, titled "Suven Life Sciences secures Three Australian Patents on NCEs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Apr · Business
Press release dated April 12, 2010, titled "Suven Life Sciences secures First Product Patent from Japanese Patent Office (JPO) for their NCE to treat Central Nervous System (CNS) disorders." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Apr · Updates
A fire accident occurred in leased premises outside of our Unit which is away from our main R&D unit at Jeedimetla, Hyderabad around 5.00 p.m on 5th April 2010. No one was injured in the accident and there was no disruption of operations at our unit
Mar 2010
29 Mar · Business
Press release dated March 29, 2010, titled "Suven Life Sciences secures 8th product patent from European Patent Office (EPO) for their NCE to treat Central Nervous System (CNS) disorders". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Mar · Business
Press release dated March 22, 2010, titled "Suven Life Sciences secures 5th Product Patent from US patent office for their NCE to treat Central Nervous System (CNS) disorders". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2010
18 Feb · Management
Abstract of terms & Memorandum under Section -302 of the Companies Act, 1956 for Appointment of Shri Venkateswarlu Jasti as Chairman and CEO of the Company and Smt Sudha Rani Jasti as Wholetime Director of the Company, circulated to the Share holders of the Company. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
27 Jan · Business
Press release dated January 27, 2010, titled " Suven Spend 34 % of Revenue on R & D for the 3rd Quarter ending Dec' 09". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jan · Board meeting
Meeting on 27 Jan 2010: “Unaudited Financial Results for the qtr ended Dec 31, 2009”